Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare.
Tarsus Pharmaceuticals (TARS) Appoints Rosemary A Crane to its Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
Home / Top News / Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette grade
Further Saturn-1 safety analysis revealed that TP-03 had a favorable safety profile with no clinically significant effect on multiple measures
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette grade
Further Saturn-1 safety analysis revealed that TP-03 had a favorable safety profile with no clinically significant effect on multiple measures
Titan study reveals the high real-world prevalence of Demodex blepharitis, with collarettes present in 58% of U.S. patients visiting an eye doctor
IRVINE, Calif., July 24, 2021 (GLOBE NEWSWIRE) Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced new data from its Saturn-1 Phase 2b/3 pivotal trial and the Titan real-world collarette prevalence study at the American Society of Cataract and Refractive Surgery (ASCRS) 2021 Annual Meeting